Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
- Citation:
- J Thorac Oncol vol 3 (10) 1159-65
- Year:
- 2008
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- Received
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- 631
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA03927, CA114558-02, CA21060, CA31946, CA31983, CA33601, CA35113, CA35421, CA37447, CA41287, CA45389, CA45418, CA45564, CA45808, CA47559, CA47577, CA47642, CA74811, CA77298, CA77440
- Corr. Author:
- Authors:
- Antonius A Miller Xiaofei F Wang Lin Gu Philip Hoffman Jamil Khatri Frank Dunphy Martin J Edelman Michael Bolger Everett E Vokes Mark R Green
- Networks:
- Study
- CALGB-30303
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adenocarcinoma, Adenocarcinoma, Bronchiolo-Alveolar, Adult, Aged, Anemia, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Darbepoetin alfa, Dose-Response Relationship, Drug, Drug Therapy, Combination, Erythropoietin, Feasibility Studies, Female, Filgrastim, Granulocyte Colony-Stimulating Factor, Hematinics, Humans, Lung Neoplasms, Male, Maximum Tolerated Dose, Mesna, Middle Aged, Neoplasm Staging, Neutropenia, Polyethylene Glycols, Prognosis, Recombinant Proteins, Survival Rate, Taxoids